SAN FRANCISCO – Sutter’s California Pacific Medical Center has become the first hospital in California and the West Coast to implant the AltaValve™ System in a patient with mitral valve disease as part of the ATLAS pivotal clinical trial. This potentially groundbreaking procedure is a critical step forward for patients whose anatomical complexities have made them ineligible for other commercially available mitral valve solutions.
“This new treatment opens the door for people suffering from symptomatic mitral regurgitation who previously had no viable treatment options, providing them with an opportunity to potentially significantly improve their quality of life,” said Dr. David Daniels, an interventional cardiologist at Sutter’s CPMC.
Dr. Daniels, alongside Dr. Christian Spies and CPMC’s cardiac care team, performed the successful procedure this month.
Building on a Legacy of Innovation
Historically, patients with mitral valve disease, or mitral valve regurgitation, have faced limited care options, often requiring invasive open-heart surgery. Over the past decade, medical advancements have introduced minimally invasive repair technologies like MitraClip™, but effective replacement options have lagged behind.
The AltaValve System is one of the first transcatheter mitral valve replacement (TMVR) devices being offered through clinical trials. Its unique atrial fixation mechanism is designed to minimize complications associated with other TMVR devices, such as obstruction of the heart’s left ventricular outflow or damage to surrounding heart structures.
“By solving these challenges, AltaValve represents a significant advancement in care for people with complex cardiac conditions,” said Dr. Ron Waksman, steering committee chair for the ATLAS trial.
Similar to other mitral valve solutions, patients treated with the AltaValve System may experience relief from symptoms such as shortness of breath and fatigue and could potentially return to daily activities within weeks of the procedure.
Did you know: Mitral valve regurgitation is the most common type of heart valve disease.
Advancing Patient Outcomes
